TNGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tango Therapeutics Inc (TNGX) is not a strong buy at this moment for a beginner investor with a long-term focus. While the stock shows some positive technical indicators and analyst optimism, the lack of recent financial growth, insider selling, and absence of strong trading signals suggest holding off for now.
The technical indicators are mixed. The MACD is positive and expanding, suggesting upward momentum. The RSI is at 78.505, indicating the stock is nearing overbought territory. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key resistance levels (R1: 24.943, with the next resistance at R2: 26.538).
Analysts have been consistently raising price targets, with the latest target at $30, reflecting optimism about the company's PRMT5 inhibitor and its potential in combination therapies. Recent leadership appointments could strengthen the company's strategic direction.
Insiders are selling heavily, with a 181.42% increase in selling activity over the last month. The company's financial performance is weak, with revenue dropping to zero in Q4 2025 and EPS declining 14.71% YoY. Additionally, Revolution's recent success may overshadow Tango's progress in the PRMT5 space.
The company's financials for Q4 2025 are concerning. Revenue dropped to zero (-100% YoY), while net income slightly improved to -$38.75M (+2.86% YoY). EPS declined to -0.29 (-14.71% YoY). Gross margin remains at 100%, but the lack of revenue growth is a significant red flag.
Analysts are optimistic, with multiple 'Buy' ratings and price targets ranging from $19 to $30. The focus is on the company's PRMT5 inhibitor and its potential in combination therapies for pancreatic and lung cancers. Positive data readouts are expected in 2026, which could act as a catalyst for the stock.
